AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04931147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC007 Matching Placebo
Description: The matching placebo for RXC007 will be administered in the form of oral capsules matched to the number of active RXC007 capsules at each dose level to 2 of the 6 participants within each cohort in Part A and Part B. For Part A, dosing frequency is one placebo dose on one occasion and for Part B, dosing frequency is single placebo doses once daily for 14 days. If required, following dose escalation data review, dosing frequency and duration may be modified in Part B.~There is no placebo intervention for Part C of the study.
Study NCT05840666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Sustained Natural Apophyseal Glide (SNAG)
Description: Application of the MWM technique developed by Brian R. Mulligan. The clinical researcher will perform and holds sustained passive segmental glide at the target joint maintaining the slack whereas the patient will actively move in the direction of pain or stiffness. These MWM techniques when applied to spinal segments or joint is called sustained natural apophyseal glide (SNAG).
Study NCT05840666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: McKenzie Method
Description: An active therapy technique involving repeated movements or sustained positions along with an educational component prescribed to the patient for of minimizing the pain and disability and increase the spinal range of motion. The method will involve the assessment of symptomatic and mechanical responses to repeated movements and sustained positions in the direction of preference. The method will be used for assessment and treatment of patients and with derangement syndrome.
Study NCT05840666 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: It includes usual physical therapy care such as Therapeutic Ultrasound, Moist Heat-pack, TENS and standard exercises.
Study NCT04846504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMBFM program with clinician coach support
Description: Clinician-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed.
Study NCT04846504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMBFM program with peer coach support
Description: Peer-delivered telephonic coaching to support participants in the Mindful Mood Balance for Moms online course for prevention of depression relapse/recurrence among perinatal women who have had prior episodes of depression but are not currently depressed. Peers will be women with lived experience of perinatal depression who are trained on the coaching protocol.
Study NCT04846504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient facing strategy intervention arm
Description: Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
Study NCT04846504 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient facing plus clinic facing strategy intervention arm
Description: Direct outreach and recruitment of participants into Mindful Mood Balance for Moms study by study teams, plus recommendation of / referral to the Mindful Mood Balance for Moms study by OB clinicians at the 4 study sites. OB clinicians will choose from printed materials (e.g., flyers, posters in exam rooms and waiting rooms, prescription pads) and electronic medical record prompts (e.g., smart lists, dot phrases) to facilitate engagement in the Mindful Mood Balance for Moms course. Participants will be women receiving prenatal care at the 4 study sites: Kaiser Permanente Colorado, Southern California, and Georgia, and HealthPartners.
Study NCT05685108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound stimulation intensity
Description: A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve.
Study NCT05685108 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound stimulation site
Description: A clinical ultrasound transducer will be placed against the abdomen or neck of an individual in order to administer insonification to the splenic nerve and the cervical vagus nerve.
Study NCT05056103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TrachFlush
Description: The attending nurses activate the TrachFlush when there are secretions present in the larger airways that need to be removed. If this results into a push of airway secretions past and above the cuff of the endotracheal tube, no further action is needed. If unsuccessful, the nurse will perform a standard tracheal suctioning procedure to remove the secretions. In a subset of patients with an endotracheal tube that allows subglottal suctioning, the exact amount of airway secretions present above the cuff will be measured each time the TrachFlush is used.
Study NCT06526572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain wave analysis using electroencephalography (EEG).
Description: Asessment of pain with objective neurophysiological assessment through brain wave analysis using electroencephalography (EEG).
Study NCT06526572 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Numerical rate Scale (NRS)
Description: Asessment of pain with the subjective numercal rate scale method (NRS
Study NCT04727866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal direct current stimulation (tsDCS) - coronal
Description: 20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with cathode over C5-C7 transverse process on target side, anode over C5-C7 transverse process on non-target side.
Study NCT06089850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluate the evolution of the psychic state of the donors (ascendants and descendants), by means of questionnaires, within the framework of haplo-identical allograft.
Description: Donors are included in the study during the pre-donation assessment. Completion of questionnaires + socio-demographic data~CSH collection visit (V1): Visit at which donors are collected for CSH donation. Completion by the donor of the questionnaires~Follow-up of donors at D90 (+/-7) post V1, D180 (+/-15D) post V1 and D360 (+/-15D) post V1. The donors participating in the study will complete the scales/questionnaires~D360: Completion by the donor of the questionnaires + semi-structured interview by telephone if accepted by the participant
Study NCT05081752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC Stentfix
Description: Stent placement with fixation of the esophageal stent using OTSC Stentfix.
Study NCT05081752 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Suturing / Endoscopic Clips
Description: Stent placement with fixation of the esophageal stent using sutures / endoscopic clips.
Study NCT04727866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal direct current stimulation (tsDCS) - caudal
Description: 20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~T1-T4 posteriorly, anode over \~C5-T1 anteriorly
Study NCT04727866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous spinal direct current stimulation (tsDCS) - rostral
Description: 20 minutes of tsDCS will be delivered at 66% of maximum tolerated intensity with DCS cathode over \~C3-C5 posteriorly, anode over \~C5-T1 anteriorly
Study NCT04727866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Description: 3 minutes of iTBS (a form of repetitive TMS) will be delivered during a 5-minute interval of DCS
Study NCT04106999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Drug infusion will be delivered intra-operatively
Study NCT04106999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline will be infused as a control drug
Study NCT04842357 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standardised video concerning clinical skill
Description: watching a video concerning clinical skills.
Study NCT06130059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Colchicine
Description: Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
Study NCT06130059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04862143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
Study NCT04862143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
Study NCT04862143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
Study NCT05260983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education and Acceptance and Commitment Therapy
Description: A brief diabetes prevention education and acceptance and commitment therapy engagement facilitation intervention. Acceptance and Commitment Therapy-informed materials (i.e. video, workbook, and activities) will retain facts about the condition, but will modify health messaging to clarify common inaccurate illness perceptions, reduce body size discrimination, and encourage psychological flexibility through framing illness perceptions, controllability awareness (i.e. ability to distinguish modifiable from unmodifiable components), non-judgmental awareness of what is occurring, willingness to allow experiences to occur, and the ability to step back from cognitions, acting according to personal values.
Study NCT05260983 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Prevention Education Only
Description: A brief standard diabetes prevention education engagement facilitation intervention modeled from the Center for Disease Control and Preventions's National Diabetes Prevention Program.
Study NCT05164822 — intervention group
Intervention type: OTHER
Intervention: Necrotizing Vasculitis
Description: Pain scale Diagnosis of necrotizing vasculitis and peripheral neuropathy, Clinical characteristics of the disease, Biological analysis, Treatment and evolution of the disease,~Questionnaires :~Neuropathy Impairment Score (NIS) sensitive sub-questionnaire that measures extremity sensitivity.~MRC (Medical Research Council), which evaluates three motor functions on each member.~RODS questionnaire on the relationship between your daily activities and your health.~BVAS (Birmingham Vasculitis Activity Score) disease activity questionnaire. VDI (Vasculitis Damage Index) questionnaire evaluates the sequelae of the disease.~Rankin Score modified to measure the degree of disability~Two tests will be performed:~EMG (electromyogram) to evaluate the electrical activity of the muscles, Walking Test of 10 meters which aims to measure the time taken to travel 10 meters.
Study NCT06538636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCP-Facing Tools
Description: PCP-facing tools will be turned on as a package: a) enhanced LCS clinical reminder including DP+ generated smart message; b) Integrated one-click DP+ full decision tool for automating personalized information about the net benefit of LCS based on patient characteristics; c) the TurboHM tool: automated Health maintenance app for tracking all preventive care, including a dedicated LCS section with personalized information
Study NCT06538636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCS team population management tools
Description: site-specific dashboard and proactive outreach toolkit
Study NCT05734508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN vaccine
Description: A live vaccine produced from the Modified Vaccinia Ankara-Bavarian Nordic strain (MVA-BN), an attenuated and non-replicating orthopox virus
Study NCT04200066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide, Tamoxifen, Maprotiline
Description: Subjects will receive a combination of temozolomide and tamoxifen for two weeks. After that, they will receive a combination of temozolomide, tamoxifen and maprotiline for the remainder of the study. All drugs are administered orally. Subjects will undergo visits at the beginning of week 3, week 5 and week 7 that will involve multiple blood draws and ECGs to evaluate for pharmacokinetics and drug interactions. Response will be assessed every two months with an MRI and patients will continue on study as long as their tumors are under control and they are tolerating the regimen.
Study NCT02629237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted education
Description: Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
Study NCT05639738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinical and instrumental measurements
Description: * Clinical evaluations~* Non-invasive instrumental measurements~* Subject's evaluations
Study NCT05481021 — intervention group
Intervention type: OTHER
Intervention: No intervention but assessing for burnout syndrome in all group
Description: Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
Study NCT05524194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Infusion
Description: Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).
Study NCT04479618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Practice
Description: A saline soaked piece of gauze, conformed to the size of the open ulcer area, will be placed over the ulcer and held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
Study NCT04479618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improvised dressing
Description: A piece of a new food-grade plastic bag, cut slightly larger than the ulcer, will be placed over the ulcer, sealed at the edges with an emollient to create an occlusive dressing. The dressing will be gently conformed to the ulcer contours to eliminate dead space, and a slit will be cut in the center to allow excess fluid to escape into a clean absorbent material placed over the slit. The device will be held in place with a wrap of stretch gauze. Ulcers will be rinsed with saline at daily dressing changes, which will be conducted by the patient after they master the procedure.
Study NCT04479618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced dressing
Description: A piece of polymeric membrane dressing, cut to extend at least 0.5cm beyond the open ulcer edges, will be placed over the ulcer and held in place with a wrap of stretch gauze. The approximate wound edges will be marked on the back of the dressing. Dressing changes will consist only of removing the dressing when the saturation level, visible through the wound backing, reaches the mark indicating the dressing edges and applying a new cut dressing. Changes will be conducted by the patient after they master the procedure.
Study NCT04885829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Prefilled Syringe
Description: 0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
Study NCT04885829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Prefilled Syringe
Description: 0.9ml Subcutaneous pre-filled syringes containing 162mg of Tocilizumab.
Study NCT05839093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior Alveolar Nerve Block Group
Description: A standard IANB injection with a conventional dental injector and a 27-G needle. After determining the injection site and performing aspiration, 1.8 mL of solution was injected at a rate of 1 mL/min to block the inferior alveolar nerve. After achieving lip anesthesia, infiltration was performed at the buccal side of the affected tooth with 0.5 mL using a normal syringe and a 27-G needle. The needle insertion point was the middle of the mesiodistal distance of the crown. Five minutes later, the teeth were isolated and the endodontic procedure was started.
Study NCT04945395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES and Conventional training
Description: The experimental group will be fitted with the Functional electrical stimulation system L300 Go to be used during 4 weeks of inpatient rehabilitation in the subacute phase after hemiplegic stroke. Settings will be adjusted continuously to enhance dorsiflexion of the affected foot during walking and mobility training.
Study NCT06019468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Envolizumab combined with radiotherapy
Description: Application of Envolizumab combined with radiotherapy for neoadjuvant treatment of locally advanced thymic cancer. Firstly, 20-40Gy radiation therapy was administered 10-20 times. Within one week after the start of radiation therapy, Envolizumab (300 mg, D1, Q3W, subcutaneous injection) was administered. Immunotherapy was maintained for 2-4 cycles, and surgery was performed after evaluation by the attending physician.
Study NCT05343702 — intervention group
Intervention type: DRUG
Intervention: priming with rocuronium
Description: Following induction (paralysis after onset of the induction effect) in routine rapid sequence intubation protocols While paralysis is applied, it is aimed to shorten the half-life of rocuronium by administering a subparalytic dose of rocuronium approximately 3-5 minutes before induction in the priming technique
Study NCT05156138 — intervention group
Intervention type: OTHER
Intervention: no interventions as it is a case control observational study
Description: no interventions as it is a case control observational study
Study NCT05106257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education (short)
Description: The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The short condition consists of two calls (30-45 minutes each) to introduce patient education topics and refer to the booklet for further information.
Study NCT05106257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ground-based walking training
Description: Participants randomized to this condition will be mailed a pedometer (3DFitBud Simple Step Counter) and instructed on its use to establish baseline steps/ day for 7 days. They will then receive a booklet with instructions to establish a walking program and three brief (10-15 minute), bi-weekly calls from a trained staff member to review step count values and engage in setting personal activity goals over the course of 6 weeks, following established exercise guidelines for individuals with COPD.
Study NCT05106257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaler training
Description: Participants randomized to this condition will receive two sessions of inhaler technique education using a virtual teach-to-goal (TTG) method in which individuals are observed using their inhaler, provided feedback, and then observed again.
Study NCT05106257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver support
Description: Participants randomized to this condition will identify an informal caregiver who is involved in their healthcare (i.e., spouse, family member, or friend), who will receive a mailed copy of the Respiratory Health Association's COPD Caregiver's Toolkit, a comprehensive informational resource to support the care of the person living with COPD. Caregivers will receive two brief (10-15 minute) check-in calls from a trained staff member. The structured content of these sessions will include providing an overview of toolkit content, identifying goals for sections(s) to review and incorporate into caregiving activities, and addressing any questions.
Study NCT05106257 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management education (long)
Description: The self-management education condition is based on the Living Well with COPD program. The program consists of a mailed booklet and structured phone counseling delivered by certified COPD educators. Topics include disease information, breathing retraining, action planning, medication use, energy conservation, and following good health habits. The long condition consists of five, weekly calls (30-45 minutes each) following a structured curriculum of patient education topics.